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Summary
A number of pharmaceutical steroid synthons are cur-
rently produced through the microbial side-chain
cleavage of natural sterols as an alternative to multi-
step chemical synthesis. Industrially, these synthons
have been usually produced through fermentative
processes using environmental isolated microorgan-
isms or their conventional mutants. Mycobacterium
smegmatismc2155 is a model organism for tuberculo-
sis studies which uses cholesterol as the sole carbon
and energy source for growth, as other mycobacterial
strains. Nevertheless, this property has not been
exploited for the industrial production of steroidic
synthons. Taking advantage of our knowledge on the
cholesterol degradation pathway of M. smegmatis
mc2155 we have demonstrated that the MSMEG_6039
(kshB1) and MSMEG_5941 (kstD1) genes encoding a
reductase component of the 3-ketosteroid 9a-hydro-
xylase (KshAB) and a ketosteroid D1-dehydrogenase
(KstD), respectively, are indispensable enzymes for
the central metabolism of cholesterol. Therefore, we
have constructed a MSMEG_6039 (kshB1) gene dele-
tion mutant of M. smegmatis MS6039 that transforms
efﬁciently natural sterols (e.g. cholesterol and phytos-
terols) into 1,4-androstadiene-3,17-dione. In addition,
we have demonstrated that a double deletion mutant
M. smegmatisMS6039-5941 [DMSMEG_6039 (DkshB1)
and DMSMEG_5941 (DkstD1)] transforms natural ster-
ols into 4-androstene-3,17-dione with high yields.
These ﬁndings suggest that the catabolism of choles-
terol in M. smegmatis mc2155 is easy to handle and
equally efﬁcient for sterol transformation than other
industrial strains, paving the way for valuating this
strain as a suitable industrial cell factory to develop a
la carte metabolic engineering strategies for the
industrial production of pharmaceutical steroids.
Introduction
Androstenedione (4-androstene-3,17-dione; AD) and
androstadienedione (1,4-androstadiene-3,17-dione; ADD)
are key intermediates of microbial steroid metabolism
(Garcıa et al., 2012). These compounds belong to the
17-keto steroid family and are used as the starting mate-
rials for the preparation of different pharmaceutical ster-
oids (Malaviya and Gomes, 2008; Donova and Egorova,
2012; Garcıa et al., 2012). These synthons can be pro-
duced by microbial side-chain cleavage of cholesterol or
phytosterols as an alternative to multi-step chemical syn-
thesis based on digoxigenin, a steroid found exclusively
in the ﬂowers and leaves of Digitalis plants, as a starting
material. Industrially, AD and ADD have been produced
through fermentative processes using wild microorgan-
isms that have been subsequently modiﬁed and opti-
mized by conventional mutagenic procedures (Donova
et al., 2005; Andor et al., 2006; Donova and Egorova,
2012; Garcıa et al., 2012). Mycobacterium spp. NRRL
3805B and 3683B capable of forming AD and ADD from
sterols, respectively, are examples of these mutants
used at industrial scale (Donova et al., 2005; Donova
and Egorova, 2012). A drawback of the AD and ADD
industrial production based on these wild strains is the
usual and concomitant accumulation of unwanted by-
products which hinder downstream processes. The use
of molecularly deﬁned mutants has been envisioned to
avoid such drawbacks, but the lack of genetic data on
the microbial catabolism of steroids has hampered the
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construction of genetically engineered mutants so far.
Nevertheless, some attempts have been conducted to
construct site-directed mutant strains of Rhodococcus
(i.e. the best characterized cholesterol-degrading organ-
ism) to produce AD, ADD and 9a-hydroxy-4-androstene-
3,17-dione (9OH-AD) from natural sterols (e.g. choles-
terol or phytosterols), but these mutants have not been
used at industrial scale yet (van der Geize et al., 2000,
2001a,b, 2002a,b, 2008; Wilbrink et al., 2011; Yeh et al.,
2014).
To create a la carte mutants able to produce AD and
ADD from cholesterol or phytosterols we have tested
Mycobacterium smegmatis mc2155 as a model strain
based on our current knowledge on sterol catabolism in
this microorganism (Fig. 1) (Garcıa et al., 2012). The 3-
ketosteroid 9a-hydroxylase (Ksh) has been proposed as
the key enzyme for ring-B opening, and therefore, the
removal of this activity should render ADD as end-pro-
duct. The Ksh enzymes of Rhodococcus and Mycobac-
terium have been characterized as two-component
monooxygenases, composed of an oxygenase (KshA)
and a ferredoxin reductase (KshB) (van der Geize et al.,
2002a; Capyk et al., 2009, 2011; Petrusma et al., 2009,
2012, 2014; Hu et al., 2010; Bragin et al., 2013; Penﬁeld
et al., 2014). Therefore, theoretically, a deletion mutant
of one of the Ksh encoding genes, i.e. kshA or kshB,
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Fig. 1. Proposed pathway for cholesterol degradation in Mycobacterium smegmatis. Cholest-4-en-3-one or any of the subsequent metabolites
from degradation of the side-chain up to (and including) AD may undergo a dehydrogenation reaction to introduce a double bond in the position
1, leading to compound cholest-1,4-diene-3-one in the case of cholest-4-en-3-one, or to the corresponding 1,2-dehydro derivatives for other
molecules. The side-chain degradation of this compounds will be identical to that of the cholest-4-en-3-one to the common intermediate 9a-
hydroxyandrosta-1,4-diene-3,17-dione (9OHAD). 3b-hydroxysteroid dehydrogenase (3b-HSD), 3-ketosteroid-D1-dehydrogenase (KstD), 3-ketos-
teroid-9a-hydroxylase (KshAB), 3-hydroxy-9,10-secoandrosta-1,3,5(10)-trien-9,17-dione (3-HSA), 3,4-dihydroxy-9,10-secoandrosta-1,3,5(10)-
trien-9,17-dione (3,4-HSA), 4,5,9,10-diseco-3-hydroxy-5,9,7-trioxoandrosta-1(10),2-diene-4-oic acid (4,9-DSHA), 3aa-H-4a(30-propionic acid)-
7ab-methylhexahydro-1,5-indanedione (HIP), 3aa-H-4a(30-propionic acid)-5a-hydroxy-7b-methylhexahydro-1-indanone (5OH-HIP), 3-hydroxy-
9,10-secoandrosten-1,3,5(10)-trien-9,17-dione dyoxigenase (HsaC), 4,5,9,10-diseco-3-hydroxy-5,9,7-trioxoandrosta-1(10),2-diene-4-oic acid
hydroxylase (HsaD), 2-hydroxy-2,4-hexadienoic acid hydratase (HsaE), 4-hydroxy-2-hydroxy-2-ketovalerate aldolase (HsaF), acetaldehyde
dehydrogenase (HsaG), HIP-CoA transferase (LpdAB and FadD3), FadE30 (Acyl-CoA dehydrogenase).
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should accumulate ADD. On the other hand, 3-ketoster-
oid D1-dehydrogenase (KstD) is the key enzyme that
transforms AD into ADD and thus, strains lacking KstD
should theoretically accumulate 9OH-AD. Finally, double
mutants in Ksh and KstD should render AD as the main
product for sterol degradation (Fig. 1) (Garcıa et al.,
2012).
Nevertheless, these previous assumptions cannot be
always easily conﬁrmed by gene inactivation since
cholesterol catabolic pathway usually presents functional
redundancy for some steps of the pathway; this means
that one catalytic step can be carried out by several
homologous enzymes. Two KstD enzymes were
reported in Rhodococcus erythropolis SQ1 (van der
Geize et al., 2000) and accordingly, targeted disruption
of only one of the kstD genes did not result on the accu-
mulation of intermediates, but the strain lacking both
dehydrogenase activities was able to convert AD into
9OH-AD stoichiometrically (van der Geize et al., 2002b).
Similarly, Fernandez de las Heras et al. (2012) have
demonstrated the existence of three KstD activities in
Rhodococcus ruber strain Chol-4 and showed that the
triple KstD mutant was able to convert AD into 9OH-AD.
However, these mutants were unable to accumulate
9OH-AD from cholesterol or phytosterols (van der Geize
et al., 2001a; Fernandez de las Heras et al., 2012).
Brzostek et al. (2009) have identiﬁed six putative KstD
enzymes within the M. smegmatis genome and a tar-
geted disruption of one of them (KstD1) resulted in par-
tial inactivation of the cholesterol degradation pathway
and the consequent accumulation of AD. More recently,
Wei et al. (2010) have identiﬁed and deleted a kstD
gene (named ksdDM) in Mycobacterium neoaurum
NwIB-01, a strain isolated from a sterol contaminated
soil that naturally accumulates ADD from phytosterols.
Interestingly, the resulting deleted mutant (named NwIB-
2) was able to accumulate AD from phytosterols, but
ADD is still present in the culture medium, suggesting
that this strain contains other KstD enzymes (Wei et al.,
2010). Three homologues of KstD have been character-
ized in M. neoaurum ATCC 25795 and thus, single dele-
tion of these genes failed to result in a stable and
maximum accumulation of 9OH-AD due to residual KstD
activities (Yao et al., 2014).
On the other hand, van der Geize et al. (2002a, 2008)
have demonstrated that Ksh mutants of R. erythropolis
SQ1 deleted in kshA or kshB genes can produce ADD
from AD, but surprisingly they do not accumulate AD,
ADD or other metabolites during sterol conversion. Inter-
estingly, the degradation of phytosterols was not
impaired in a kshA- mutant and rates of degradation
were comparable to those of the parent strain, suggest-
ing that Rhodococcus has alternative enzymes to catab-
olize phytosterols. Moreover, the kshB- mutant failed to
cleave the side-chain of sterols and, although phytos-
terols were oxidized to their stenone derivatives, they
were not metabolized further, suggesting that kshB could
be also involved in the degradation of sterol side-chain
in Rhodococcus (van der Geize et al., 2002a). The situa-
tion can be more complex taking into account that some
strains of Rhodococcus may contain up to ﬁve KshA
homologous proteins, each displaying unique steroid
induction patterns and substrate ranges, conﬁrmed that
the 9a-hydroxylation can take place at different steps of
steroid oxidation (Petrusma et al., 2011).
On the basis of our knowledge on cholesterol metabo-
lism in M. smegmatis (Uhıa et al., 2012) we detected
that this organism has several important differences with
the sterol catabolism in Rhodococcus and we anticipated
that these differences might render M. smegmatis as a
suitable cell factory for the metabolic manipulation of this
pathway. The results presented below demonstrate this
hypothesis and show that M. smegmatis is an ideal cell
factory to develop metabolic engineering strategies for
the industrial production of AD, ADD or other steroid
intermediates using natural sterols as feedstock.
Results
Identiﬁcation of Ksh and KstD enzymes in M. smegmatis
In contrast to the frequent observation that the compo-
nents of bacterial multicomponent oxygenases are
encoded in a single operon, the kshA and kshB genes
encoding Ksh activity in Rhodococcus (van der Geize
et al., 2002a) or in M. tuberculosis (Cole et al., 1998)
are located far from each other in the genome. Never-
theless, using the sequence of the annotated kshA and
kshB genes from Rhodococcus (van der Geize et al.,
2002a, 2008) and M. tuberculosis (Capyk et al., 2009)
as probes, we have localized the corresponding ortho-
logues in M. smegmatis (Table 1). This analysis
revealed that there are at least two genes encoding
putative oxygenase components, named kshA1 and
kshA2, and two genes encoding putative reductase com-
ponents, named kshB1 and kshB2. This means that
M. smegmatis could produce theoretically four different
Ksh hydroxylases, i.e. Ksh1 (KshA1B1), Ksh2
(KshA2B2), Ksh3 (KshA1B2), Ksh4 (KshA2B1). How-
ever, a detailed analysis of the upstream sequences of
these genes showed that only the MSMEG_5925
(kshA1) and MSMEG_6039 (kshB1) genes are preceded
by promoters inducible by cholesterol, having the con-
sensus operator sequence for the binding of the KstR
repressor, one of the regulators of cholesterol catabolism
(named KstR regulon) (Kendall et al., 2007). Moreover,
microarray expression experiments carried out on
M. smegmatis indicate that kshA1 and kshB1 are
induced 1.9-fold and 7.0-fold, respectively, in cholesterol
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with respect to glycerol (Table 1) (Uhıa et al., 2012). On
the contrary, kshA2 and kshB2 are not induced by
cholesterol under the tested conditions (Table 1) (Uhıa
et al., 2012). These results strongly suggest that most
probably only Ksh1 encoded by kshA1B1 is involved in
the metabolism of cholesterol in M. smegmatis.
Among the six putative kstD genes identiﬁed in the
M. smegmatis genome by Brzostek et al. (2009) that
might encode the KstD-like activity only the
MSMEG_5941 (kstD1) gene is controlled by a promoter
containing the consensus KstR operator sequence and
is differentially expressed in the presence of cholesterol
(Table 1) (Uhıa et al., 2012). This observation suggests
that in M. smegmatis most probably only kstD1 was
involved in the catabolism of cholesterol.
Therefore, based on these analyses we anticipated
the hypothesis that in M. smegmatis a single deletion of
kshB1 (or kshA1) and a double deletion of kshB1 (or
kshA1) and kstD1 might be sufﬁcient to generate
mutants able to accumulate ADD or AD, respectively,
when cultured in the presence of sterols.
Construction of the DkshB1 M. smegmatis mutant
As mentioned above, to eliminate the two-component
Ksh1 hydroxylase activity (KshA1B1) in M. smegmatis,
we assumed that it was enough to delete the
MSMEG_6039 (kshB1) gene encoding the reductase
component, thus we constructed the MS6039 mutant
(DkshB1) (Fig. S1). Ksh1 activity can be eliminated
either by deleting kshB1 or kshA1 (or both), but we
decided to test the single deletion of kshB1 instead of
kshA1, because in the absence of the corresponding
oxygenase component, the reductase component of mul-
ticomponent oxygenases usually acts as a gratuitous
scavenger of reduction power, generating futile cycles
that might reduce the efﬁciency of the biotransformation
process (Galan et al., 2000; Blank et al., 2010) and
therefore, in this sense, it can be more convenient to
suppress the reductase instead the oxygenase compo-
nent. However, it is also true that other reductase
enzymes present in the cell could replace their function.
Nevertheless, we also decided to delete kshB1 because
the effect of the deletion of the kshB homologous gene
has already been analysed in Rhodococcus (van der
Geize et al., 2002a,b) and we would like to compare the
performance of M. smegmatis having the same gene
deletion.
The engineered MS6039 mutant (DkshB1) was
unable to efﬁciently grow in cholesterol or phytosterols
as a sole carbon and energy source when compared
with the wild-type strain (Fig. 2A). However, the mutant
perfectly grows using glycerol as a carbon source
(Fig. 2B). To conﬁrm that the deletion of kshB1 was
responsible for the observed phenotype, we trans-
formed the MS6039 mutant with the plasmid pMV6039
harbouring the kshB1 gene. Figure 2D shows that the
complemented MS6039 (pMV6039) strain recovered the
capacity to grow in sterols as a sole carbon and energy
source. These results conﬁrmed that kshB1 plays an
essential role in the catabolism of sterols in M. smeg-
matis. In addition, considering that the MS6039 mutant
is unable to efﬁciently grow in sterols even at long incu-
bation periods, we can conclude that the KshB1 reduc-
tase activity of Ksh1 cannot be replaced by other
mycobacterial reductases, i.e. KshB2 or other KshB-like
reductases, in the tested conditions, either because
they are not expressed in these conditions or because
they cannot interact with the KshA1 oxygenase
component.
These experiments also revealed that wild-type
M. smegmatis is able to use efﬁciently different phytos-
terols as a carbon and energy source (Fig. 2C), and this
is remarkable because the capacity of this strain to grow
Table 1. In silico analysis of M. smegmatis mc2 155 genome.
Protein Genea M. smegmatis mc2 155 Protein (aa length) Identityb (%) KstR-regulon operator Induction foldc
KshA MSMEG_5925 383 67 Yes 7.00
MSMEG_2870 386 53 No 1.00
KshB MSMEG_6039 353 63 Yes 1.88
MSMEG_2893 351 56 No 1.21
KstD MSMEG_5941 566 65 Yes 13.00
MSMEG_4864 587 39 No -1.46
MSMEG_2869 558 40 No -1.17
MSMEG_2867 522 31 No -1.14
MSMEG_4870 546 30 No -1.35
MSMEG_5835 547 17 No 1.14
a. Gene identiﬁcations correspond to the last annotation of M. smegmatis genome and are different to the annotations described by Brzostek
et al. (2005).
b. Identities were established using the proteins of R. jostii RHA1 as reference.
c. Induction fold was calculated comparing gene expression in M. smegmatis cultured in cholesterol verus glycerol containing media (Uhıa
et al., 2012).
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on a mixture of phytosterols has not been well docu-
mented in the literature so far.
On the other hand, the slight growth of MS6039 in the
presence of sterols suggested that the mutant was able
to degrade their side-chain and predicted a possible
accumulation of metabolic intermediates in the culture
medium. As expected, Figure 4 shows the accumulation
of ADD in the culture medium of MS6039 mutant when
cultured in shake ﬂasks, whereas M. smegmatis wild-
type strain completely mineralizes cholesterol (or phytos-
terols) and does not accumulate any intermediate in
these culture conditions (data not shown). The ADD
molar yield for the transformation of cholesterol or phy-
tosterols was 91% for both feedstocks. Nevertheless, we
have also detected the presence of small amounts of
22-hydroxy-23,24-bisnorchol-1,4-dien-3-one (1,4-HBC,
20-hydroxymethylpregna-1,4-dien-3-one) as a by-product
(Fig. 4C and D).
In addition, we have tested the production of ADD
from phytosterols in 5- and 20-l stirred jar bioreactors
using higher concentrations of phystosterols (20 g l1)
as substrate to study the industrial potential of MS6039
mutant strain. By carrying several replicates of these
experiments in different operational conditions, we con-
cluded that between 55% and 70% of added phytos-
terols are consumed and the molar yield to ADD varies
from 67% to 80%, depending on the bioreactor scale.
AD was also obtained in a yield from consumed phytos-
terols between 22% and 30%; other by-products, such
as 1,4-HBC were detected as traces (Fig. S2). These
experiments carried out at high sterol concentrations
showed a signiﬁcant contamination of unconverted AD
suggesting that KstD activity is a bottleneck for the com-
plete transformation of phytosterols into ADD at industrial
scale. This problem can be overcome by changing the
operational conditions (e.g. preinoculation growth, inocu-
lation conditions, bioreactor agitation conﬁguration, aera-
tion ﬂow, composition of culture medium, pH control,
substrate additions, etc.) in combination with the overex-
pression of kstD genes in MS6039 that lead to a signiﬁ-
cant increase in ADD/AD ratio (Gadea personal
communication).
The results contrast with the data obtained with the
equivalent kshB- mutant of R. erythropolis strain SQ1
(RG4 mutant), which only accumulates sitostenone from
b-sitosterol, because apparently, the RG4 mutant does
not degrade the side-chain of b-sitosterol. To explain this
performance, it was proposed that the KshB reductase
from R. erythropolis was not only involved in the produc-
tion of 9OH-AD, but also in sterol side-chain removal
(van der Geize et al., 2002b). In M. smegmatis, the
absence of KshB1 does not hinder the complete degra-
dation of the sterol side-chain (see Discussion).
Construction of the DkshB1 and DkstD1 M. smegmatis
double mutant
According to our previous genomic analysis, it should be
possible to produce AD from sterols in M. smegmatis by
eliminating the KstD activity in the MS6039 mutant.
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Fig 2. Growth curves of M. smegmatis mc2155, mutants and complemented strains cultured in shake ﬂasks with different carbon sources. (A)
Strains cultured with 0.4 g l1 of cholesterol (mc2155 (squares), MS6039 (circles) and MS6039-5941 (triangles)); (B) Strains cultured with
18 mM glycerol (mc2155 (squares), MS6039 (circles) and MS6039-5941 (triangles)); (C) Strains cultured with 0.4 g l1 of phytosterols (mc2155
(squares), MS6039 (circles) and MS6039-5941 (triangles)); (D) Gene complementation of MS6039 mutant strain cultured with 1.8 mM of choles-
terol (mc2155 (pMV261) (diamonds), MS6039 (pMV261) (squares) and MS6039 (pMV6039) (circles)). The data reported are the averages of
three different assays.
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Therefore, to test this hypothesis, we constructed the
M. smegmatis MS6039-5941 double mutant (DkstD1,
DkshB1) by deleting the MSMEG_5941 (kstD1) gene in
the MS6039 (DkshB1) mutant (Fig. S1). As expected,
the MS6039-5941 (DkshB1-DkstD1) double mutant was
unable to efﬁciently grow in cholesterol or phytosterols
as the sole carbon and energy source, but the double
mutant grows in glycerol at the same rate than the wild-
type strain (Fig. 2B).
Accordingly to our predictions, when the MS6039-
5941 double mutant was cultured in minimal media con-
taining glycerol as carbon and energy source and
cholesterol (or phytosterols) as feedstock, the culture
yields a large accumulation of AD in shake ﬂasks
(Fig. 4A and B). The AD molar yields for sterol transfor-
mations were 90% and 84% when cholesterol or phytos-
terols were used as substrates respectively.
Interestingly, in these culture conditions, small amounts
of 22-hydroxy-23,24-bisnorchol-4-en-3-one (4-HBC, 20-
hydroxymethylpregna-4-en-3-one) were accumulated
during the biotransformation (Fig. 4C and D).
These results support the hypothesis that although
M. smegmatis has six putative KstD dehydrogenases,
the KstD1 enzyme encoded by the MSMEG_5941 gene
is the main KstD used for sterol catabolism in this bac-
terium. This observation contrasts with other cholesterol-
degrading bacteria, where several KstD dehydrogenases
are involved in the metabolism of sterols (van der Geize
et al., 2000, 2002b; Fernandez de las Heras et al.,
2012; Yao et al., 2014).
The MS6039-5941 double mutant was tested in 2-l jar
bioreactor in the presence of 10 g l1 of phytosterols. An
almost complete transformation of phytosterols into AD
(88–90%), 4-HBC (10–11%) and very small amounts of
ADD and 1,4-HBC were detected in several replicates of
this experiment (Fig. S3).
Interestingly, the accumulation of small amounts of
ADD observed in the bioreactor experiments suggests
that one of the other identiﬁed kstD2, kstD3, kstD4,
kstD5 or kstD6 homologous genes (Table 1) is some-
what active in the mutant. Thus, to further improve the
AD production yield, this residual KstD activity should be
identiﬁed and eliminated. Moreover, in this sense, it will
be also important to understand why the three last car-
bons at C-17 are not efﬁciently converted into propionyl-
CoA, rendering 4-HBC and 1,4 HBC as by-products of
the pathway.
Discussion
The ﬁrst remarkable ﬁnding presented above is the
experimental demonstration that M. smegmatis mc2155
is able to efﬁciently metabolize mixtures of phytosterols
as carbon and energy sources through the same
catabolic pathway utilized to mineralize cholesterol
(Fig. 1) (Uhıa et al., 2012). This ﬁnding is important
because it supports the proposal of considering
M. smegmatis as a useful cell factory for the industrial
production of steroidic synthons from raw sterols. Sur-
prisingly, in spite of the large accumulated knowledge on
M. smegmatis mc2155 biology, this organism has not
been used as a cell factory for this industrial purpose so
far. The only case reported in the literature is an antibi-
otic resistant mutant deposited as M. smegmatis VKPM
Ac-1552 in the Russian National Collection of Industrial
Microorganisms (VKPM) that appears to transform ster-
ols into AD (Russian Federation Patent no. 2 126 837
(1999), reviewed in Donova (2007)).
The observation that the growth of M. smegmatis
mc2155 in sterols is impaired by a deletion of the kshB1
gene (MSMEG_6039) suggests that KshB1 is the main
reductase component of the two-component KshAB 9a-
hydroxylase in the cholesterol degradative pathway of
this organism. Apparently, this reductase activity is not
redundant in M. smegmatis and thus, it cannot be
replaced by similar enzymes, as it has been demon-
strated for other key enzymes of the pathway (Uhıa
et al., 2011). In addition, the kshB1 gene does not
appear to be critical for the degradation of the side-chain
of sterols in M. smegmatis, as suggested in Rhodococ-
cus (van der Geize et al., 2002a), and therefore, its
absence does not impair an efﬁcient transformation of
sterols into AD or ADD in the mutant strain.
On the other hand, the signiﬁcant accumulation of AD
in the MS6039-5941 (DkshB1-DkstD1) double mutant
ascribes a fundamental role to the kstD1 gene
(MSMEG_5941) in the catabolism of cholesterol. Never-
theless, in this mutant, we have observed some enzyme
redundancy because we were able to detected small
amounts of ADD when high concentrations of phytos-
terols are transformed. Therefore, we can conclude that
at least one of the other ﬁve putative KstD enzymes
identiﬁed in M. smegmatis mc2155 (Table 1) can also
replace this function, but this alternative KstD activity is
very low and does not appear to fulﬁl the relevant func-
tion observed in other cholesterol-degrading strains (van
der Geize et al., 2000, 2002b; Fernandez de las Heras
et al., 2012; Yao et al., 2014).
The results presented in this work suggest that the
metabolism of sterols in M. smegmatis mc2155 concern-
ing to the two central/key enzymes investigated, i.e.
KstD and Ksh, is less redundant than in Rhodococcus.
Perhaps, the low redundancy of these central enzymes
can explain why many strains currently used at industrial
scale to transform phytosterols into AD, ADD or 9OH-AD
are mycobacterial mutants obtained by conventional
mutagenesis, i.e. because single mutations like those
produced in this work might render a producer strain.
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Genomic analyses of some of these industrial mutants
have conﬁrmed this hypothesis (data not shown).
Another interesting difference observed between the
sterol catabolism of Mycobacterium and Rhodococcus is
the presence of 4-HBC and 1,4-HBC alcohols as meta-
bolic by-products in the cultures of our mutants (Figs 3C,
D and 4C, D). It has been described that the cultures of
equivalent Rhodococcus mutants only accumulate the
corresponding acids (Wilbrink et al., 2011; Yeh et al.,
2014). The RG32 mutant of Rhodococcus rhodochrous
DSM43269, a mutant completely devoid of Ksh by inacti-
vation of ﬁve kshA genes, was able to produce very
small amounts of ADD from b-sitosterol (7% molar) but
large amounts of 3-oxo-23,24-bisnorchola-1,4-dien-22-
oic acid (1,4-BNC) (67% molar) (Wilbrink et al., 2011). A
kshB- mutant of Rhodococcus equi USA-18 was also
able to produce ADD and 1,4-BNC from sterols in similar
molar ratios (Yeh et al., 2014).
In this regard, 4-HBC alcohol was detected many
years ago together with AD during phytosterol transfor-
mations performed by the industrial strain of Mycobac-
terium sp. NRRL B-3805 (Marsheck et al., 1972). This
alcohol was postulated as a side reaction product but
not as a physiological intermediate of the major pathway
leading to production of C-17-ketonic products (Mar-
sheck et al., 1972). It has been proposed that 4-HBC
and 1,4-HBC derive from 4-BNC and 1,4-BNC, respec-
tively, by the action of a carboxyl-reductase by one or
two consecutive enzymatic steps (Szentirmai, 1990; Xu
et al., 2016). Nevertheless, these carboxyl-reductases
have not been identiﬁed in mycobacteria yet (Xu et al.,
2016). Assuming this hypothesis, these enzymes should
not be active, or very low active, in Rhodococcus, since
only the 4-BNC/1,4-BNC acids are detected in this
organism (Yeh et al., 2014).
The accumulation of these C-22 intermediates sug-
gests that the elimination of the last isopropyl group of
the sterol side-chain seems to be highly dependent of
the 9a-hydroxylation by Ksh. We assume that in the
absence of 9a-hydroxylation, the enzymes responsible
for removing the last propionic acid of the side-chain at
C-17, i.e. the postulated acyl-CoA-dehydrogenase,
enoyl-CoA-hydratase and aldol-lyase enzymes (Garcıa
et al., 2012), do not work efﬁciently. This inefﬁciency can
be caused because they are feedback inhibited by the
accumulation of AD and/or ADD, or because the real
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Fig 3. Production of ADD by the MS6039 mutant in shake ﬂasks. ADD is represented by triangles. (A) 9 mM glycerol + 0.4 g l1 of cholesterol
(circles) used as substrates; (B) 9 mM glycerol + 0.4 g l1 of phytosterols (diamonds) used as substrates; (C) Analysis by CG-MS of the prod-
ucts after 96 h of incubation on phytosterols. (1) ADD, (2) cholestenone (internal standard), and (3) 1,4-HBC. (D) Chemical structure and frag-
mentation pattern of 1,4-HBC. The data reported are the averages of three different assays.
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substrates of these enzymes are the 9a-hydroxy deriva-
tives of 1,4-BNC-CoA or 4-BNC-CoA. In this sense, it
has been demonstrated that the best substrate of Ksh
from M. tuberculosis is 4-BNC-CoA and 1,4-BNC-CoA
(Capyk et al., 2011), suggesting that 9a-hydroxylation
occurs before the release of the last propionic acid at C-
17. If the previous 9a-hydroxylation of the steroid is criti-
cal to be recognized as a substrate for some of the
enzymes involved in the release of the side-chain, this
might explain why in Rhodococcus the absence of KshB
impairs the complete degradation of the sterol side-chain
(van der Geize et al., 2002a). Then, most probably the
homologous enzymes of Mycobacterium are efﬁcient
enough on non-hydroxylated substrates and thus, the
9a-hydroxylation of sterols is not so critical to allow the
complete side-chain degradation. In M. neoaurum ATCC
25795, the accumulation of 4-HBC and 1,4-HBC was
only detected after the deletion of the hsd4A gene
coding for a dual-functional enzyme with both 17b-hydro-
xysteroid dehydrogenase and b-hydroxyacyl-CoA dehy-
drogenase activities. However, these compounds are not
the substrates of the Hsd4A in vitro (Xu et al., 2016).
This means that some partial or complete blockage of
the side-chain degradation might cause the accumulation
of 4-HBC or 1,4-HBC as by-products. This blockage can
be caused not only by speciﬁc mutations, but also by
retro-inhibitions of the enzymes due to the accumulation
of certain intermediates when the cells are cultured with
high concentrations of sterols.
During the course of this work, Xu et al. (2015) have
described a double (DkshA1, DkstD1) mutant of Mycobac-
terium sp. (apparently a derivative of M. neoaurum NwIB-
02 (DkstD1) (Wei et al., 2010) that accumulates AD, ADD,
1,4-HBC and 4-HBC at different concentrations depending
of fermentation temperature when cultured on phytosterols.
This result conﬁrmed that mycobacteria accumulate C-22
alcohols instead of the corresponding C-22 acids. Interest-
ingly, they have also demonstrated that the residual KstD
activity is not active on 9OH-AD (Xu et al., 2015) suggest-
ing that a D1-dehydrogenation by KstD precedes Ksh
hydroxylation. Remarkably, in contrast with our MS6039-
5941 (DkshB1-DkstD1) double mutant, this M. neoaurum
mutant still retains other Ksh and KstD active isoenzymes,
because this mutant completely metabolized high amounts
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Fig 4. Production of AD by the MS6039-5941 mutant in shake ﬂasks. AD is represented by squares. (A) 9 mM glycerol + 0.4 g l1 of choles-
terol (circles) used as substrates; (B) 9 mM glycerol + 0.4 g l1 of phytosterols (diamonds) used as substrates; (C) Analysis by GC/MS of the
products after 96 h of culture on phytosterols. (1) AD, (2) cholestenone (internal standard) and (3) 4-HBC. (D) Chemical structure and fragmen-
tation pattern of 4-HBC. The data reported are the averages of three different assays.
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of the sterol nucleus (39.8% by moles), which considerably
reduces the ﬁnal conversion yield of the process (Xu et al.,
2015). This result strongly reinforces our proposal that
M. smegmatis can be considered as a good cell factory to
produce steroid synthons by metabolic engineering.
The ﬁnding that MS6039 and MS6039-5941 mutants
can produce large amounts of ADD and AD from natural
sterols, respectively, constitutes an experimental demon-
stration that metabolic engineering can be implemented
in a model mycobacterial system like M. smegmatis
mc2155 to generate pharmaceutical steroid synthons at
industrial scale using a rational metabolic engineering
approach. In fact, these engineered strains are already
competing at industrial scale, i.e. under industrial opera-
tional conditions, with the existing strains isolated from
environmental sources that were modiﬁed for their indus-
trial use long time ago by conventional mutagenic proce-
dures. Thus, our results lay the foundations for the
valuation of M. smegmatis as a useful tool to develop a
la carte engineered strains as cell factories to transform
with high efﬁciency natural sterols into valuable pharma-
ceutical steroids.
Experimental procedures
Chemicals
Cholest-4-en-3-one was purchased from Fluka (Stein-
heim, Germany). ADD and AD were purchased from TCI
America. Chloroform and glycerol were purchased from
Merck (Darmstardt, Germany). Cholesterol, N,O-bis(tri-
methylsilyl) triﬂuoroacetamide (BSTFA), gentamicin, pyri-
dine, Tween 80 and tyloxapol were from Sigma
(Steinheim, Germany). Oligonucleotides were from
Sigma-Genosys.
Bacterial strains and culture conditions
The strains as well as the plasmids used in this work
are listed in Table 2. M. smegmatis mc2155 and its
mutant strains were grown at 37°C in an orbital shaker
at 200 r.p.m. Middlebrook 7H9 broth medium (Difco)
containing 10% albumin-dextrose-catalase supplement
(Becton Dickinson, New Jersey, USA) and 0.05% Tween
80 was used as rich medium. 7H10 agar (Difco) plates
supplemented with albumin-dextrose-catalase were also
used for solid media. Middlebrook 7H9 broth medium
(Difco) without albumin-dextrose-catalase supplements
containing 18 mM glycerol was used as a minimal med-
ium. The minimal culture media used for the production
of AD or ADD contained a mixture of 9 mM glycerol and
0.4 g l1 cholesterol, or a mixture of 9 mM glycerol and
0.4 g l1 of phytosterols. Commercial phytosterols (pro-
vided by Gadea Biopharma, Spain) contained a mixture
of different sterols (w/w percentage): brassicasterol
(2.16%), stigmasterol (8.7%), campesterol (36.8%) and
b-sitosterol (54.4%). Cholesterol and phytosterols were
Table 2. Bacterial strains and plasmids used in this study.
Strains or plasmids Genotype and/or description Source or reference
Strains
Mycobacterium smegmatis
mc2155 ept-1, mc²6 mutant efﬁcient for electroporation Snapper et al. (1990)
MS6039 M. smegmatis mc2155 DMSMEG_6039 This study
MS6039-5941 M. smegmatis mc2155 DMSMEG_6039 DMSMEG_5941 This study
mc2155 (pMV261) mc2155 strain harbouring plasmid pMV261 This study
MS6039 (pMV261) MS6039 strain harbouring plasmid pMV261 This study
MS6039 (pMV6039) MS6039 strain harbouring plasmid pMV6039 This study
Escherichia coli
DH10B F-, mcrA, D (mrrhsdRMS-mcrBC), Φ80dlacZDM15,
DlacX74, deoR, recA1, araD139, D(ara-leu)7697,
galU, galK, k-, rpsL, endA1, nupG
Invitrogen
Plasmids
pJQ200x Suicide vector used to perform allelic exchange
mutagenesis in Mycobacterium, P15A ori,sacB, Gmr, xylE
Jackson et al. (2001)
pJQ6039 pJQ200x containing one fragment upstream and
another downstream of MSMEG_6039 gene
This study
pJQ5941 pJQ200x containing one fragment upstream and
another downstream of MSMEG_5941 gene
This study
pGEM-T Easy E. coli cloning vector; Ampr Promega
pGEMT6039 pGEMT-Easy harbouring the MSMEG_6039
gene encoding KshB1 from M. smegmatis mc2 155
This study
pMV261 Mycobacterium/E. coli shuttle vector with the
kanamycin resistance aph and the promoter
from the hsp60 gene from M. tuberculosis
Stover et al. (1991)
pMV6039 pMV261 harbouring the MSMEG_6039 gene
encoding KshB1 from M. smegmatis mc2 155
This study
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dissolved in 10% tyloxapol prior to its addition to the
minimal medium when assayed in ﬂasks. Due to the low
solubility of cholesterol and phytosterols, stock solutions
were warmed at 80°C in agitation, sonicated in a bath
for 1 h and then autoclaved. Gentamicin (5 lg/ml) was
used for selection of M. smegmatis mutant strains when
appropriate.
Bioreactor experiments were performed using the cul-
ture media previously described (Herrington and Spas-
sov, 2003) containing a vegetal oil to dissolve
phytosterols and corn steep liquor as supplementary car-
bon and nitrogen sources. The bioconversion experi-
ments were performed in stainless steel (20-l) or glass
(2- and 5-l) jar bioreactors with efﬁcient stirring. The
entire process was performed at 37°C.
Escherichia coli DH10B strain was used as a host for
cloning. It was grown in rich LB medium at 37°C in an
orbital shaker at 200 r.p.m. LB agar plates were used for
solid media. Gentamicin (10 lg ml1), ampicillin
(100 lg ml1) or kanamycin (50 lg ml1), were used for
plasmid selection and maintenance in this strain.
Gene deletions
The knock-out strains of M. smegmatis named MS6039
and MS6039-5941 were constructed by homologous
recombination using the pJQ200x plasmid, a derivative
of the suicide pJQ200 vector that does not replicate in
Mycobacterium (Jackson et al., 2001). The strategy con-
sist, for each gene, in generating two fragments of
~700 bp, the ﬁrst one containing the upstream region
and few nucleotides of the 50end of the gene and the
second one containing the downstream region and few
nucleotides of the 30end of the gene, that are ampliﬁed
by PCR using the oligonucleotides described in Table 3
and M. smegmatis genomic DNA as template (Fig. S1).
M. smegmatis genomic DNA extraction was performed
as described (Uhıa et al., 2011). The two fragments gen-
erated were digested with the corresponding enzymes
and cloned into the plasmid pJQ200x using E. coli
DH10B competent cells as described (Uhıa et al., 2011).
Plasmid DNA from E. coli DH10B recombinant strains
was extracted using the High Pure Plasmid Puriﬁcation
Kit (Roche, Basel, Switzerland), according to the manu-
facturer’s instructions. This procedure was performed for
genes MSMEG_6039 and MSMEG_5941, generating the
pJQ6039 and pJQ5941 plasmids respectively. Plasmid
pJQ6039 was electroporated into competent M. smeg-
matis mc2155 to obtain strain MS6039. Plasmid
pJQ5941 was electroporated into competent MS6039
cells to obtain MS6039-5941 strain. Single cross-overs
were selected on 7H10 agar plates containing gentam-
icin and the presence of the xylE gene encoded in
pJQ200x was conﬁrmed by spreading catechol over the
single colonies of electroporated M. smegmatis. The
appearance of a yellow coloration indicates the presence
of the xylE gene. Colonies were also contra-selected in
10% sucrose. A single colony was grown in 10 ml of
7H9 medium with 5 lg ml1 gentamicin up to an optical
density of 0.8–0.9 and 20 ll of a 1:100 dilution was pla-
ted onto 7H10 agar plates with 10% sucrose to select
for double cross-overs. Potential double cross-overs (su-
crose-resistant colonies) were screened for gentamicin
sensitivity and the absence of the xylE gene. The mutant
strains MS6039 and MS6039-5941 were analysed by
PCR and DNA sequencing to conﬁrm the deletions of
MSMEG_6039 and MSMEG_5941 genes.
Construction of pMV6039 plasmid
To isolate the kshB1 gene from M. smegmatis mc2 155
genomic DNA was extracted and ampliﬁed by PCR using
the primers MSMEG_6039F (CGGAATTCTGACCTAAG
GAGGTGAATGTGACTGATGAGCCCCTGGG) and MS
MEG_6039R (CGAAGCTTCTATTCGTCGTAGGTGAC
TTCG). The ampliﬁed fragment of 1092 bp was cloned
into the commercial plasmid pGEM-T Easy to generate
pGEMT6039 plasmid that was transformed in E. coli
DH10B competent cells. The cloned fragment was further
digested with EcoRI and HindIII to clone into pMV261, a
shuttle plasmid that replicates in E. coli and Mycobac-
terium generating the plasmid pMV6039 that was
Table 3. Primers used in this study.
Primer Sequence (50–30)a Use
MSMEG_6039 up F ctagctcgagccagttgtgcacaccgatg MSMEG_6039 deletion (ampliﬁcation of upstream region)
MSMEG_6039 up R ctagactagtgcagcgtcaggaactggc MSMEG_6039 deletion (ampliﬁcation of upstream region)
MSMEG_6039 down F ctagactagtggtgcacatggagatcaacg MSMEG_6039 deletion (ampliﬁcation of downstream region)
MSMEG_6039 down R ctagtctagagtaccagtcgatcggtgtc MSMEG_6039 deletion (ampliﬁcation of downstream region)
MSMEG_5941 up F ctagactagtgatgttgcgaatgtcgatgtc MSMEG_5941 deletion(ampliﬁcation of upstream region)
MSMEG_5941 up R ctagtctagaccaccacaacgtcgtactcc MSMEG_5941 deletion(ampliﬁcation of upstream region)
MSMEG_5941 down F ctagtctagaccatgacattcggttacctgg MSMEG_5941 deletion(ampliﬁcation of downstream region)
MSMEG_5941 down R ctaggagctcgcagggagatctcgaaatcg MSMEG_5941 deletion (ampliﬁcation of downstream region)
a. Restriction sites are underlined.
ª 2016 The Authors. Microbial Biotechnology published by John Wiley & Sons Ltd and Society for Applied Microbiology, Microbial
Biotechnology, 10, 138–150
Steroid production by metabolic engineering 147
transformed into E. coli DH10B to generate the recombi-
nant strain E. coli DH10B (pMV6039). Once the sequence
of the pMV6039 was checked it was used to transform
electrocompetent cells of M. smegmatis MS6039 generat-
ing the M. smegmatis MS6039 (pMV6039) recombinant
strain.
GC/MS analyses
To perform GC/MS analysis, culture aliquots (0.2 ml)
were extracted twice at various extents of incubation
with an equal volume of chloroform. Previously to its
extraction, 10 ll of a solution of 10 mM cholesterol
(when phytosterols were used as substrate) or 10 mM
cholestenone (when cholesterol was used as substrate)
dissolved in chloroform were added to the aliquots as
internal standards. The chloroform fraction was concen-
trated by evaporation and the trimethylsilyl ether deriva-
tives were formed by reaction with 50 ll of BSTFA and
50 ll of pyridine and heating at 60°C for 45 min. Calibra-
tion standards were derivatized in the same way. The
GC/MS analysis was carried out using an Agilent 7890A
gas chromatograph coupled to an Agilent 5975C mass
detector (Agilent Technologies, Palo Alto, CA, USA).
Mass spectra were recorded in electron impact (EI)
mode at 70 eV within the m/z range 50–550. The chro-
matograph was equipped with a 30 m 9 0.25 mm i.d.
capillary column (0.25_m ﬁlm thickness) HP-5MS (5%
diphenyl 95% dimethylpolysiloxane from Agilent Tech-
nologies). Working conditions in the sample were as fol-
lows: split ratio (20:1), injector temperature, 320°C;
column temperature 240°C for 3 min, then heated to
320°C at 5°C min1.For quantiﬁcation of the peak area,
the quantitative masses were 329 + 458 m/z for choles-
terol; 343 + 384 m/z for cholestenone; 382 + 472 m/z
for campesterol; 394 + 484 m/z for stigmasterol;
357 + 486 m/z for b-sitosterol; 244 + 286 m/z for AD
and 122 + 284 m/z for ADD in selected ions of monitor-
ing. EI mass spectra and retention data were used to
assess the identity of compounds by comparing them
with those of standards in the NIST Mass Spectral Data-
base and commercial standards (NIST 2011).
High-performance liquid chromatography analyses
To perform high-performance liquid chromatography
(HPLC) analysis, samples (1 g) were withdrawn and
extracted with 10 mL of ethyl acetate during two hours
in a magnetic stirrer. One aliquot was centrifugated
10 min at 10 000 r.p.m. and supernatant was diluted
1:10 in acetonitrile. Samples were ﬁltered (0.2 lm pore
size) prior to the chromatographic analysis. The HPLC
analysis was carried out using a Waters liquid chro-
matograph with a PDA detector system. A Phenomenex
C18 column (Nucleosil C18, 100 A, 250 9 4.6 mm,
5 lm particles) was employed and the temperature of
the column was ﬁxed in 50°C. Working conditions were
as follows: the mobile phase was a mixture water: ace-
tonitrile: acetic acid (48: 52: 0.1 v/v); ﬂow rate was
1.1 mL min1; the injection volumen was 10 ll. Peaks
were monitorized at 240 nm and calibrations were per-
formed using highly puriﬁed standards of each
compound.
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Supporting information
Additional Supporting Information may be found online in
the supporting information tab for this article:
Fig. S1. Construction of the mutant strains MS6039 and
MS6039-5941. The polylinker restriction sites of the suicide
plasmid pJQ200x are indicated (B, BamHI; Sp, SpeI; X,
XbaI; N, NotI; Bs, BstXI; S, SacI).
Fig. S2. Production of ADD from phytosterols by the
MS6039 mutant in 5-L jar bioreactor. Analysis by HPLC of
the transformation products at 120 h of culture. (1) solvent
front; (2) ADD; (3) AD; (4) 1,4-HBC.
Fig. S3. Production of AD from phytosterols by the
MS6039-5941 mutant in 2-L jar bioreactor. Analysis by GC/
MS of the transformation products at 96 h of culture. (1)
AD; (2) ADD; (3) 4- HBC; (4) 1,4-HBC; (5) campesterol; (6)
stigmasterol; (7) b-sitosterol.
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